Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study.
(retrospective) matched case-control study
VigiBase
cardiovascular conditions
immune checkpoint inhibitor
myocarditis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Nov 2020
23 Nov 2020
Historique:
received:
27
10
2020
revised:
17
11
2020
accepted:
21
11
2020
entrez:
26
11
2020
pubmed:
27
11
2020
medline:
27
11
2020
Statut:
epublish
Résumé
Although rare, immune checkpoint inhibitor (ICI)-related myocarditis can be life-threatening, even fatal. In view of increased ICI prescription, identification of clinical risk factors for ICI-related myocarditis is of primary importance. This study aimed to assess whether pre-existing cardiovascular (CV) patient conditions are associated with the reporting of ICI-related myocarditis in VigiBase, the WHO global database of suspected adverse drug reactions (ADRs). In a (retrospective) matched case-control study, 108 cases of ICI-related myocarditis and 108 controls of ICI-related ADRs other than myocarditis were selected from VigiBase. Drugs labeled as treatment for CV conditions (used as a proxy for concomitant CV risk factors and/or CV diseases) were found to be associated more strongly with the reporting of ICI-related myocarditis than with other ICI-related ADRs (McNemar's chi-square test of marginal homogeneity:
Identifiants
pubmed: 33238481
pii: cancers12113480
doi: 10.3390/cancers12113480
pmc: PMC7700285
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
NCHS Data Brief. 2012 Aug;(103):1-8
pubmed: 23101933
Trends Cardiovasc Med. 2020 Jun 1;:
pubmed: 32497572
Drugs Aging. 2019 Oct;36(10):927-938
pubmed: 31317421
Cephalalgia. 2014 Jan;34(1):5-13
pubmed: 23921799
Am J Cardiol. 2020 Jun 15;125(12):1920-1926
pubmed: 32312493
Int J Cardiol. 2019 Dec 1;296:113-121
pubmed: 31327516
J Cancer Res Clin Oncol. 2019 Feb;145(2):511-521
pubmed: 30539281
Int J Cardiol. 2019 Dec 1;296:124-126
pubmed: 31472949
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
Cardiovasc Res. 2019 Apr 15;115(5):854-868
pubmed: 30715219
Drug Saf. 2020 Oct;43(10):999-1009
pubmed: 32564242
Int J Med Inform. 2009 Dec;78(12):e97-e103
pubmed: 19230751
Lancet. 2018 Mar 10;391(10124):933
pubmed: 29536852
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
BMJ. 2020 Apr 6;369:m736
pubmed: 32253223
Target Oncol. 2020 Aug;15(4):449-466
pubmed: 32725437
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Lancet Oncol. 2018 Jun;19(6):737-746
pubmed: 29778737
J Thorac Oncol. 2019 Sep;14(9):1628-1639
pubmed: 31121324
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Cancer Immunol Res. 2020 Jul;8(7):851-855
pubmed: 32350001
Target Oncol. 2019 Apr;14(2):205-221
pubmed: 30927173
Ther Innov Regul Sci. 2020 Sep;54(5):1116-1122
pubmed: 32078733
BMC Cancer. 2019 Jun 10;19(1):559
pubmed: 31182049
Int J Cancer. 2020 Sep 15;147(6):1753-1754
pubmed: 32159861
Ann Oncol. 2017 Oct 1;28(10):2377-2385
pubmed: 28945858
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
JAMA Oncol. 2019 Aug 22;:
pubmed: 31436802
Oncologist. 2019 Nov;24(11):e1148-e1155
pubmed: 31036771